Tumor necrosis factor as a therapeutic target of rheumatologic disease

Bibliography

• KAVANAUGH A, COHEN S, CUSH JJ: The evolving use of TNF inhibitors in rheumatoid arthritis. J. Rheumatol. (2004) 31(10):1881-1884.
   PubMed Web of Science ®Google Scholar
• BRAUN J, BARALIAKOS X, LISTING J, SIEPER J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-TNF agents infliximab and etanercept. Arthritis Rheum. (2005) 52(8):2447-2451.
   PubMed Web of Science ®Google Scholar
• BRAUN J, BRANDT J, LISTING J et al.: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 359(9313):1187-1193.
   PubMed Web of Science ®Google Scholar
• BRANDT J, KHARIOUZOV A, LISTING J et al.: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. (2003) 48(6):1667-1675.
   PubMed Web of Science ®Google Scholar
• VAN DER HEIJDE D, DIJKMANS B, GEUSENS P et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. (2005) 52(2):582-591.
   PubMedGoogle Scholar
• MEASE PJ, GOFFE BS, METZ J et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356(9227):385-390.
   PubMed Web of Science ®Google Scholar
• MEASE PJ, KIVITZ AJ, BURCH FX et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. (2004) 50(7):2264-2272.
   PubMed Web of Science ®Google Scholar
• ANTONI CE, KAVANAUGH A, KIRKHAM B et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. (2005) 52(4):1227-1236.
   PubMed Web of Science ®Google Scholar
• VAN DER HEIJDE D, KIVITZ A, SCHIFF MH et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2006) 54(7):2136-2146.
   PubMedGoogle Scholar
• PROBERT CS, HEARING SD, SCHREIBER S et al.: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut (2003) 52(7):998-1002.
   PubMed Web of Science ®Google Scholar
• SANDS BE, TREMAINE WJ, SANDBORN WJ et al.: Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm. Bowel Dis. (2001) 7(2):83-88.
   PubMed Web of Science ®Google Scholar
• RUTGEERTS P, SANDBORN WJ, FEAGAN BG et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. (2005) 353(23):2462-2476.
   PubMed Web of Science ®Google Scholar
• GILES JT, BATHON JM: Serious infections associated with anticytokine therapies in the rheumatic diseases. J. Inten. Care Med. (2004) 19(6):320-334.
   PubMedGoogle Scholar
• WOLFE F, MICHAUD K, ANDERSON J, URBANSKY K: Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. (2004) 50(2):372-379.
   PubMed Web of Science ®Google Scholar
• BROWN SL, GREENE MH, GERSHON SK, EDWARDS ET, BRAUN MM: TNF antagonist therapy and lymphoma development: twenty-six cases reported to the food and drug administration. Arthritis Rheum. (2002) 46(12):3151-3158.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH A: Economic issues with new rheumatologic therapeutics. Curr. Opin. Rheumatol. (2007) 19(3):272-276.
   PubMed Web of Science ®Google Scholar
• BANSBACK NJ, ARA R, BARKHAM N et al.: Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology (Oxford) (2006) 45(8):1029-1038.
   PubMedGoogle Scholar
• CARSWELL EA, OLD LJ, KASSEL RL et al.: An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA (1975) 72(9):3666-3670.
   PubMed Web of Science ®Google Scholar
• CHOY EH, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. (2001) 344(12):907-916.
   PubMed Web of Science ®Google Scholar
• BAZZONI F, BEUTLER B: The TNF ligand and receptor families. N. Engl. J. Med. (1996) 334(26):1717-1725.
   PubMed Web of Science ®Google Scholar
• BLACK RA, RAUCH CT, KOZLOSKY CJ et al.: A metalloproteinase disintegrin that releases TNF-α from cells. Nature (1997) 385(6618):729-733.
   PubMed Web of Science ®Google Scholar
• SACCA R, CUFF CA, LESSLAUER W, RUDDLE NH: Differential activities of secreted lymphotoxin-α3 and membrane lymphotoxin-α1β2 in lymphotoxin-induced inflammation: critical role of TNF receptor 1 signaling. J. Immunol. (1998) 160(1):485-491.
   PubMed Web of Science ®Google Scholar
• FELDMANN M, ELLIOTT MJ, WOODY JN, MAINI RN: Anti-TNF-α therapy of rheumatoid arthritis. Adv. Immunol. (1997) 64:283-350.
   PubMed Web of Science ®Google Scholar
• BRENNAN FM, CHANTRY D, JACKSON A, MAINI R, FELDMANN M: Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet (1989) 2(8657):244-247.
   PubMed Web of Science ®Google Scholar
• VEALE DJ, BARNES L, ROGERS S, FITZGERALD O: Immunohistochemical markers for arthritis in psoriasis. Ann. Rheum. Dis. (1994) 53(7):450-454.
   PubMed Web of Science ®Google Scholar
• LALOUX L, VOISIN MC, ALLAIN J et al.: Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann. Rheum. Dis. (2001) 60(4):316-321.
   PubMed Web of Science ®Google Scholar
• RITCHLIN C, HAAS-SMITH SA, HICKS D et al.: Patterns of cytokine production in psoriatic synovium. J. Rheumatol. (1998) 25(8):1544-1552.
   PubMed Web of Science ®Google Scholar
• RITCHLIN CT, HAAS-SMITH SA, LI P, HICKS DG, SCHWARZ EM: Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J. Clin. Invest. (2003) 111(6):821-831.
   PubMed Web of Science ®Google Scholar
• VEALE DJ, RITCHLIN C, FITZGERALD O: Immunopathology of psoriasis and psoriatic arthritis. Ann. Rheum. Dis. (2005) 64(Suppl. 2):II26-II29.
   PubMed Web of Science ®Google Scholar
• FEARON U, REECE R, SMITH J, EMERY P, VEALE DJ: Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann. NY Acad. Sci. (1999) 878:619-621.
   PubMed Web of Science ®Google Scholar
• COSTELLO P, BRESNIHAN B, O'FARRELLY C, FITZGERALD O: Predominance of CD8+ T lymphocytes in psoriatic arthritis. J. Rheumatol. (1999) 26(5):1117-1124.
   PubMed Web of Science ®Google Scholar
• BRAUN J, BOLLOW M, NEURE L et al.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. (1995) 38(4):499-505.
   PubMed Web of Science ®Google Scholar
• GROM AA, MURRAY KJ, LUYRINK L et al.: Patterns of expression of TNF-α, TNF-β, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum. (1996) 39(10):1703-1710.
   PubMed Web of Science ®Google Scholar
• BAETEN D, KRUITHOF E, VAN DEN BOSCH F et al.: Immunomodulatory effects of anti-TNF-α therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum. (2001) 44(1):186-195.
   PubMed Web of Science ®Google Scholar
• HOCHBERG MC, SPECTOR TD: Epidemiology of rheumatoid arthritis: update. Epidemiol. Rev. (1990) 12:247-252.
   PubMed Web of Science ®Google Scholar
• FELSON DT, ANDERSON JJ, BOERS M et al.: American college of rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. (1995) 38(6):727-735.
   PubMed Web of Science ®Google Scholar
• VAN DER HEIJDE DM VTHM, VAN RIEL PL, VAN DE PUTTE LB: Development of a disease activity score based on judgment in clinical practice by rheumatologists. J. Rheumatol. (1993) 20:579-581.
   PubMedGoogle Scholar
• KAVANAUGH A, ST CLAIR EW, MCCUNE WJ, BRAAKMAN T, LIPSKY P: Chimeric anti-TNF-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J. Rheumatol. (2000) 27(4):841-850.
   PubMed Web of Science ®Google Scholar
• MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-TNF-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT study group. Lancet (1999) 354(9194):1932-1939.
   PubMed Web of Science ®Google Scholar
• LIPSKY PE VDHD, ST CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. (2000) 343:1594-1602.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. (1999) 130(6):478-486.
   PubMed Web of Science ®Google Scholar
• KLARESKOG L, VAN DER HEIJDE D, DE JAGER JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet (2004) 363(9410):675-681.
   PubMed Web of Science ®Google Scholar
• KEYSTONE EC, KAVANAUGH AF, SHARP JT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-TNF monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. (2004) 50(5):1400-1411.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-TNF-α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. (2003) 48(1):35-45.
   PubMed Web of Science ®Google Scholar
• BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.; THE PREMIER STUDY: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. (2006) 54(1):26-37.
   PubMed Web of Science ®Google Scholar
• GENOVESE MC, BATHON JM, MARTIN RW et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. (2002) 46(6):1443-1450.
   PubMed Web of Science ®Google Scholar
• BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. (2000) 343(22):1586-1593.
   PubMed Web of Science ®Google Scholar
• ST CLAIR EW, VAN DER HEIJDE DM, SMOLEN JS et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. (2004) 50(11):3432-3443.
   PubMed Web of Science ®Google Scholar
• VAN DER HEIJDE D: How to read radiographs according to the Sharp/van der Heijde method. J. Rheumatol. (1999) 26(3):743-745.
   PubMedGoogle Scholar
• FRIES JF, SPITZ P, KRAINES RG, HOLMAN HR: Measurement of patient outcome in arthritis. Arthritis Rheum. (1980) 23(2):137-145.
   PubMed Web of Science ®Google Scholar
• MARSHALL NJ, WILSON G, LAPWORTH K, KAY LJ: Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study. Rheumatology (Oxford) (2004) 43(8):1034-1038.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH AF, RITCHLIN CT: Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J. Rheumatol. (2006) 33(7):1417-1421.
   PubMed Web of Science ®Google Scholar
• SALVARANI C, OLIVIERI I, CANTINI F, MACCHIONI L, BOIARDI L: Psoriatic arthritis. Curr. Opin. Rheumatol. (1998) 10(4):299-305.
   PubMedGoogle Scholar
• SHBEEB M, URAMOTO KM, GIBSON LE, O'FALLON WM, GABRIEL SE: The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA 1982 – 1991. J. Rheumatol. (2000) 27(5):1247-1250.
   PubMed Web of Science ®Google Scholar
• GELFAND JM, GLADMAN DD, MEASE PJ et al.: Epidemiology of psoriatic arthritis in the population of the United States. J. Am. Acad. Dermatol. (2005) 53(4):573.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH A, CASSELL S: Outcome measures in psoriatic arthritis. Curr. Rheumatol. Rep. (2005) 7(3):195-200.
   PubMedGoogle Scholar
• ANTONI C, KRUEGER GG, DE VLAM K et al.: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. (2005) 64(8):1150-1157.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH A, ANTONI CE, GLADMAN D et al.; THE INFLIXIMAB MULTINATIONAL PSORIATIC ARTHRITIS CONTROLLED TRIAL (IMPACT): Results of radiographic analyses after 1 year. Ann. Rheum. Dis. (2006) 65(8):1038-1043.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH A, ANTONI C, KRUEGER GG et al.: Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann. Rheum. Dis. (2006) 65(4):471-477.
   PubMed Web of Science ®Google Scholar
• MEASE PJ, GLADMAN DD, RITCHLIN CT et al.: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. (2005) 52(10):3279-3289.
   PubMed Web of Science ®Google Scholar
• CLEGG DO, REDA DJ, MEJIAS E et al.: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study. Arthritis Rheum. (1996) 39(12):2013-2020.
   PubMed Web of Science ®Google Scholar
• FREDRIKSSON T, PETTERSSON U: Severe psoriasis – oral therapy with a new retinoid. Dermatologica (1978) 157(4):238-244.
   PubMedGoogle Scholar
• KHAN M: Update on spondyloarthropathies. Ann. Intern. Med. (2002) 136:886-906.
   Google Scholar
• CHORUS AM, MIEDEMA HS, BOONEN A, VAN DER LINDEN S: Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann. Rheum. Dis. (2003) 62(12):1178-1184.
   PubMed Web of Science ®Google Scholar
• VAN DENDERN JC VDPD, NUMOHAMED MT et al.: Double blind, randomized, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann. Rheum. Dis. (2005) 64:1761-1764.
   PubMedGoogle Scholar
• GARRETT S, JENKINSON T, KENNEDY LG et al.: A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J. Rheumatol. (1994) 21(12):2286-2291.
   PubMed Web of Science ®Google Scholar
• CALIN A, GARRETT S, WHITELOCK H et al.: A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J. Rheumatol. (1994) 21(12):2281-2285.
   PubMed Web of Science ®Google Scholar
• JENKINSON TR, MALLORIE PA, WHITELOCK HC et al.: Defining spinal mobility in ankylosing spondylitis (AS). The bath AS metrology index. J. Rheumatol. (1994) 21(9):1694-1698.
   PubMed Web of Science ®Google Scholar
• DOUGADOS M, VAN DER LINDEN S, JUHLIN R et al.: The European spondylarthropathy study group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. (1991) 34(10):1218-1227.
   PubMed Web of Science ®Google Scholar
• BRAUN J, BRANDT J, LISTING J et al.: Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum. (2003) 48(8):2224-2233.
   PubMed Web of Science ®Google Scholar
• BRAUN J, BRANDT J, LISTING J et al.: Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann. Rheum. Dis. (2005) 64(2):229-234.
   PubMed Web of Science ®Google Scholar
• BRAUN J, BARALIAKOS X, BRANDT J et al.: Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) (2005) 44(5):670-676.
   PubMed Web of Science ®Google Scholar
• GORMAN JD, SACK KE, DAVIS JC Jr: Treatment of ankylosing spondylitis by inhibition of TNF-α. N. Engl. J. Med. (2002) 346(18):1349-1356.
   PubMed Web of Science ®Google Scholar
• DAVIS JC Jr, VAN DER HEIJDE D, BRAUN J et al.: Recombinant human TNF receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. (2003) 48(11):3230-3236.
   PubMed Web of Science ®Google Scholar
• DAVIS JC, VAN DER HEIJDE DM, BRAUN J et al.: Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann. Rheum. Dis. (2005) 64(11):1557-1562.
   PubMed Web of Science ®Google Scholar
• CALIN A, DIJKMANS BA, EMERY P et al.: Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann. Rheum. Dis. (2004) 63(12):1594-1600.
   PubMed Web of Science ®Google Scholar
• DAVIS J KA, SCHIFF M et al.: Major clinical response and partial remission in ankylosing spondylitis subjects treated with adalimumab: the ATLAS trial. Arthritis Rheum. (2005) 52(Suppl. 9):S208.
   Google Scholar
• RUDWALEIT M, BARALIAKOS X, LISTING J et al.: Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann. Rheum. Dis. (2005) 64(9):1305-1310.
   PubMed Web of Science ®Google Scholar
• SIEPER J, BARALIAKOS X, LISTING J et al.: Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 years of treatment with the anti-TNF agent infliximab. Rheumatology (Oxford) (2005) 44(12):1525-1530.
   PubMed Web of Science ®Google Scholar
• DAVIS JC, VAN DER HEIJDE D, DOUGADOS M, WOOLLEY JM: Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum. (2005) 53(4):494-501.
   PubMed Web of Science ®Google Scholar
• LAMPRECHT P, VOSWINKEL J, LILIENTHAL T et al.: Effectiveness of TNF-α blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) (2002) 41(11):1303-1307.
   PubMed Web of Science ®Google Scholar
• BOOTH AD, JEFFERSON HJ, AYLIFFE W, ANDREWS PA, JAYNE DR: Safety and efficacy of TNF-α blockade in relapsing vasculitis. Ann. Rheum. Dis. (2002) 61(6):559.
   PubMedGoogle Scholar
• SANDBORN WJ, HANAUER SB, KATZ S et al.: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2001) 121(5):1088-1094.
   PubMed Web of Science ®Google Scholar
• DEN BROEDER AA, JOOSTEN LA, SAXNE T et al.: Long term anti-TNF-α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann. Rheum. Dis. (2002) 61(4):311-318.
   PubMed Web of Science ®Google Scholar
• LORENZ HM, GRUNKE M, HIERONYMUS T et al.: In vivo blockade of TNF-α in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2. J. Rheumatol. (2000) 27(2):304-310.
   PubMed Web of Science ®Google Scholar
• BRENNAN FM, BROWNE KA, GREEN PA et al.: Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-TNF-α (cA2) therapy. Br. J. Rheumatol. (1997) 36(6):643-650.
   PubMedGoogle Scholar
• CATRINA AI, LAMPA J, ERNESTAM S et al.: Anti-tumour necrosis factor (TNF)-α therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford) (2002) 41(5):484-489.
   PubMed Web of Science ®Google Scholar
• CHARLES P, ELLIOTT MJ, DAVIS D et al.: Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J. Immunol. (1999) 163(3):1521-1528.
   PubMed Web of Science ®Google Scholar
• PALEOLOG EM, HUNT M, ELLIOTT MJ et al.: Deactivation of vascular endothelium by monoclonal anti-TNF-α antibody in rheumatoid arthritis. Arthritis Rheum. (1996) 39(7):1082-1091.
   PubMed Web of Science ®Google Scholar
• PALEOLOG E YS, MCCLOSEKEY RV et al.: Angiogenesis as a therapeutic target in rheumatoid arthritis: serum vascular endothelial growth factor is decreased by anti-TNF-α therapy. Clin. Exp. Rheumatol. (1998) 16:232.
   Google Scholar
• BONGARTZ T, SUTTON AJ, SWEETING MJ et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA (2006) 295(19):2275-2285.
   PubMed Web of Science ®Google Scholar
• OLSEN NJ, STEIN CM: New drugs for rheumatoid arthritis. N. Engl. J. Med. (2004) 350(21):2167-2179.
   PubMed Web of Science ®Google Scholar
• LISTING J, STRANGFELD A, KARY S et al.: Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. (2005) 52(11):3403-3412.
   PubMed Web of Science ®Google Scholar
• DIXON WG, WATSON K, LUNT M et al.: Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-TNF therapy: results from the British society for rheumatology biologics register. Arthritis Rheum. (2006) 54(8):2368-2376.
   PubMed Web of Science ®Google Scholar
• KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a TNF-α-neutralizing agent. N. Engl. J. Med. (2001) 345(15):1098-1104.
   PubMed Web of Science ®Google Scholar
• KAPETANOVIC MC, SAXNE T, SJOHOLM A et al.: Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) (2006) 45(1):106-111.
   PubMed Web of Science ®Google Scholar
• KAINE J KA, BIRBARA C, LUO AY: Abilities to develop protective antibodies to pneuococcal and influenza vaccine are maintained in rheumatoid arthritis patients treated with adalimumab. Arthritis Rheum. (2006) 54(Suppl. 9):515-516.
   PubMedGoogle Scholar
• WATSON KD DW, HYRICH KL et al.: Influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis (RA): results from the BSR biologics register (BSRBR). Rheumatology (Oxford) (2006) 45:I10-I12.
   Google Scholar
• ASKLING J, FORED CM, BRANDT L et al.: Risks of solid cancers in patients with rheumatoid arthritis and after treatment with TNF antagonists. Ann. Rheum. Dis. (2005) 64(10):1421-1426.
   PubMed Web of Science ®Google Scholar
• WOLFE F, MICHAUD K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-TNF therapy in 18,572 patients. Arthritis Rheum. (2004) 50(6):1740-1751.
   PubMed Web of Science ®Google Scholar
• ASKLING J, FORED CM, BAECKLUND E et al.: Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to TNF antagonists. Ann. Rheum. Dis. (2005) 64(10):1414-1420.
   PubMed Web of Science ®Google Scholar
• BAECKLUND E, ILIADOU A, ASKLING J et al.: Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. (2006) 54(3):692-701.
   PubMed Web of Science ®Google Scholar
• MOHAN N, EDWARDS ET, CUPPS TR et al.: Demyelination occurring during anti-TNF-α therapy for inflammatory arthritides. Arthritis Rheum. (2001) 44(12):2862-2869.
   PubMed Web of Science ®Google Scholar
• TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The lenercept multiple sclerosis study group and the University of British Columbia MS/MRI analysis group. Neurology (1999) 53(3):457-465.
   PubMedGoogle Scholar
• VAN OOSTEN BW, BARKHOF F, TRUYEN L et al.: Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-TNF antibody cA2. Neurology (1996) 47(6):1531-1534.
   PubMedGoogle Scholar
• CHARLES PJ, SMEENK RJ, DE JONG J, FELDMANN M, MAINI RN: Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to TNF-α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. (2000) 43(11):2383-2390.
   PubMed Web of Science ®Google Scholar
• ANKER SD, COATS AJ: How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int. J. Cardiol. (2002) 86(2-3):123-130.
   PubMed Web of Science ®Google Scholar
• WOLFE F, MICHAUD K: Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-TNF therapy. Am. J. Med. (2004) 116(5):305-311.
   PubMed Web of Science ®Google Scholar
• MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-TNF-α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. (1998) 41(9):1552-1563.
   PubMed Web of Science ®Google Scholar
• LEE SJ, KAVANAUGH A: Adverse reactions to biologic agents: focus on autoimmune disease therapies. J. Allergy Clin. Immunol. (2005) 116(4):900-905.
   PubMed Web of Science ®Google Scholar
• GENOVESE MC, COHEN S, MORELAND L et al.: Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. (2004) 50(5):1412-1419.
   PubMed Web of Science ®Google Scholar
• WEINBLATT M, COMBE B, COVUCCI A et al.: Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. (2006) 54(9):2807-2816.
   PubMed Web of Science ®Google Scholar
• DOAN QV, CHIOU CF, DUBOIS RW: Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J. Manag. Care Pharm. (2006) 12(7):555-569.
   PubMed Web of Science ®Google Scholar
• WONG JB: Cost-effectiveness of anti-TNF agents. Clin. Exp. Rheumatol. (2004) 22(5 Suppl. 35):S65-S70.
   Google Scholar
• SMOLEN JS, HAN C, VAN DER HEIJDE D et al.: Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum. (2006) 54(3):716-722.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH A, ANTONI C, MEASE P et al.: Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J. Rheumatol. (2006) 33(11):2254-2259.
   PubMed Web of Science ®Google Scholar
• JOIS RN, LEEDER J, GIBB A et al.: Low-dose infliximab treatment for ankylosing spondylitis – clinically- and cost-effective. Rheumatology (Oxford) (2006) 45(12):1566-1569.
   PubMed Web of Science ®Google Scholar
• BOONEN A: A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis. Nat. Clin. Pract. Rheumatol. (2006) 2(10):546-553.
   PubMedGoogle Scholar
• VAN DER HEIJDE D, HAN C, DEVLAM K et al.: Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum. (2006) 55(4):569-574.
   PubMedGoogle Scholar
• KOBELT G, ANDLIN-SOBOCKI P, MAKSYMOWYCH WP: The cost-effectiveness of infliximab (remicade) in the treatment of ankylosing spondylitis in Canada. J. Rheumatol. (2006) 33(4):732-740.
   PubMed Web of Science ®Google Scholar
• GOEKOOP-RUITERMAN YPM, DE VRIES-BOUWSTRA JK, ALLAART CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study). Arthritis Rheum. (2005) 52(12):3381-3390.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ FB, STOINOV S et al.: Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26 week, placebo-controlled Phase III study (PRECISE 1). Gastroenterology (2006) 130:A107.
   Google Scholar
• SCHREIBER S K-KM, LAWRANCE I et al.: Certolizumab pegol, a humanised anti-TNF pegylated FAb' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a Phase III study (PECISE). Gut (2005) 65(Suppl. VII):A82.
   Google Scholar
• BINGHAM C KJ, METTESON EL et al.: One-year results of golimumab compared with placebo in patients with active RA despite treatment with methotrexate: a Phase II, randomized, double-blind, placebo-controlled, dose-ranging trial. (ACR 2006: Abstract 2123) (2006).
   Google Scholar